



EUROPEAN MEDICINES AGENCY  
SCIENCE MEDICINES HEALTH

Public Declaration of Interests and Confidentiality Undertaking of  
European Medicines Agency (EMA),  
Scientific Committee members and experts

Public declaration of interests

I, **Francesco Rodeghiero**

Organisation/Company: Hematology Project Foundation

Country: Italy

do hereby declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

2.1 Employment

No interest declared

2.2 Consultancy

Period	Company	Products	Therapeutic Indication
01/2009-(current)	Amgen	Romiplostim	ITP
10/2015-(current)	Novartis	eltrombopag	ITP
03/2016-06/2017	MedImmune	MEDI4920	ITP
03/2016-(current)	Argenx	ARGX 113	ITP
09/2016-10/2016	Octapharma	Delivery of a speech on VWD Diagnosis at a scientific meeting organized by the Karolinska Institute /Uppsala University	
09/2020-(current)	UCB	To better understand ITP landscape, treatment algorithms, standard of care in different regions, as well as understanding the research and education gaps.	

2.3 Strategic advisory role

No interest declared

2.4 Financial interests

Classified as public by the European Medicines Agency

2

No interest declared

## 2.5 Principal investigator

Period	Company	Products	Therapeutic Indication
01/2019-(current)	Novartis	eltrombopag	ITP
01/2019-(current)	Argenx	ARGX 113	ITP

## 2.6 Investigator

Period	Company	Products	Therapeutic Indication
03/2017-(current)	GIMEMA non profit Foundation partially funded by pharmaceutical companies	Principal role in conducting a nation-wide registry on active ITP	ITP

## 2.7 Grant / Funding to organisation /institution

Company	Subject Matter
Novartis	Contribution to Hematology Project Foundation (HPF) a not for profit organization (Vicenza, Italy) for a structured initiative with a dual aim: to improve the awareness of ITP across Europe, providing continuous educational action and to improve the understanding of pathophysiological, diagnostic and therapeutic aspects of ITP in adults and children through the proposal of investigations in critical areas. I will not be paid for this activity by HPF.
Amgen	Contribution to Hematology Project Foundation (HPF) a not for profit organization (Vicenza, Italy) for organizing two consensus meetings with the aim of standardizing information on a national scale regarding efficacy data and the response to the treatment of ITP patients. I will not be paid for this activity by HPF.

## 2.8 Close family member interest

No interest declared

## 2.9 Repurposing of a medicinal product

No interest declared

## 2.10 Any other interests or facts

All incomes related to section 2.7 were provided only and directly to the non profit foundation, of which I am the Scientific Director on a non-paid voluntary basis.

## 2.11 CAT member or alternate

Classified as public by the European Medicines Agency

No interest declared

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.
- Not to disclose (or authorise any other person to disclose) in any way to any third party any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to clearly indicate that the views are my own if acting in my own capacity or those of the EMA, Committee, Working Party, Expert Group or other group if acting on behalf that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

Full Name:	Francesco Rodeghiero
Date:	2020-12-11

*For Definitions of activities etc, refer to Policy on Handling of competing interests / Electronic DOI template*